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Abstract
Background: Lymph node metastasis in endometrial cancer significantly decreases survival rate. Few data on the
influence of intratumoral lymphatic microvessel density (LMVD) on survival in endometrial cancer are available. Our
aim was to assess the intratumoral LMVD of endometrial carcinomas and to investigate its association with classical
pathological factors, lymph node metastasis and survival.
Methods: Fifty-seven patients with endometrial carcinoma diagnosed between 2000 and 2008 underwent
complete surgical staging and evaluation of intratumoral LMVD and other histologic variables. Lymphatic
microvessels were identified by immunohistochemical staining using monoclonal antibody against human
podoplanin (clone D2-40) and evaluated by counting the number of immunostained lymphatic vessels in 10 hot
spot areas at 400× magnification. The LMVD was expressed by the mean number of vessels in these 10 hot spot
microscopic fields. We next investigated the association of LMVD with the clinicopathologic findings and prognosis.
Results: The mean number of lymphatic vessels counted in all cases ranged between 0 and 4.7. The median value
of mean LMVD was 0.5, and defined the cut-off for low and high LMVD. We identified low intratumoral LMVD in
27 (47.4%) patients and high LMVD in 30 (52.6%) patients. High intratumoral LMVD was associated with lesser
miometrial and adnaexal infiltration, lesser cervical and peritoneal involvement, and fewer fatal cases. Although
there was lower lymph node involvement among cases with high LMVD, the difference did not reach significance.
No association was seen between LMVD and FIGO staging, histological type, or vascular invasion. On the other
hand, low intratumoral LMVD was associated with poor outcome. Seventy-five percent of deaths occurred in
patients with low intratumoral LMVD.
Conclusion: Our results show association of high intratumoral LMVD with features related to more localized
disease and better outcome. We discuss the role of lymphangiogenesis as an early event in the endometrial
carcinogenesis.
Background
Endometrial cancer is the most frequent gynecologic
malignancy in the western world. The death rate has
increased during the most recent decades, probably due to
an increase in life span and coexisting medical
comorbidities [1]. The most important prognostic factors
in endometrial cancer are histological type, grade, lymph
node status, deep myometrial invasion, and stage [2,3].
Approximately 72% of endometrial cancers are stage I,
12% stage II, 13% stage III, and 3% stage IV (1). Five year
survival is about 90% in disease confined to the uterus, but
drops to 60% when lymph nodes are positive [4]. Lymph
node metastasis is a complex, multi-step biological process
initialized by tumor cells, involving stroma invasion, new
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lymphatic vessel formation, and spread through lymphatic
vessels to lymph node. Understanding how cancer cells
gain access to lymphatic channels and develop metastases
is of great interest for development of new therapeutic
strategies targeted against members of the signaling path-
ways involved in the lymphangiogenesis process.
The growth of lymphatic vessels largely depends on
many growth factors, such as vascular endothelial
growth factor-C and -D (VEGF-C and VEGF-D), platelet
derived growth factor-BB (PDGF-BB) and hepatocyte
growth factor[5]. However, in cancer, these known lym-
phangiogenic factors lead to simultaneous stimulation of
angiogenesis and lymphangiogenesis [6]. Lymphatic
microvessel density (LMVD) is one of the ways to evalu-
ate lymphangiogenesis. It was poor studied due to the
difficulties associated with detecting and characterizing
lymphatic markers. Currently, several molecules specifi-
cally expressed in lymphatic endothelial cells, such as
podoplanin, LYVE1, and the homeobox gene prox-1,
have enabled a more precise study of the lymphatic vas-
culature and the molecular mechanisms involved in
lymphangiogenesis [7]. LMVD has been investigated in
many tumors, particularly those characterized by lym-
phatic dissemination, such as cervical carcinomas [8-10],
but there are few studies that have evaluated LMVD in
endometrial carcinomas, and results have been conflict-
ing [11,12].
Therefore, the aim of this retrospective study was to
evaluate the relationship between intratumoral LMVD,
as well as other histologic variables, and the incidence
of lymph node metastasis and overall survival of patients




This study retrospectively analyzed patients with endo-
metrial cancer treated at the Instituto Brasileiro de Con-
trole do Cancer (IBCC), a reference Cancer Center in
São Paulo, Brazil, between 2000 and 2008. This cohort
of 57 patients included 28 (49.1%) with stage I disease, 4
(7.0%) with stage II disease, 22 (38.5%) with stage III
disease, and 3 (5.2%) with stage IV disease, classified
according to the 2009 revised International Federation
of Gynecology and Obstetrics (FIGO) system [13]. Age
of patients ranged from 46 to 89 years (67.4 ± 10.27 y).
All patients had undergone surgical staging hysterect-
omy with a sample of pelvic lymph nodes. The number
of lymph nodes excised ranged from 3 to 49 (21.5 ±
12.44), and they were positive in 22 (38.6%) and negative
in 35 (61.4%) cases. Paraortic lymph nodes were
assessed in 27 cases and nine of them were involved by
the neoplasia. The follow-up ranged from 6 to 144
months (mean 39.54 ± 29.98 months). Twelve patients
died of their disease between 6 and 108 months after
the diagnosis (median 21.5 months). Data about myo-
metrial, cervical, adnexal and peritoneal involvement,
were retrieved from the medical records. This study was
approved by the Department of Obstetrics and Gynecol-
ogy Scientific Committee of the Faculdade de Medicina
da Universidade de São Paulo, by the Ethical Committee
for Research Projects of the Hospital das Clinical da
Faculdade de Medicina da Universidade de São Paulo
(Comissão de Ética para Análise de Pesquisa - CAPPesq)
(process number 0728/08), and by the Ethical Commit-
tee for Research of the Instituto Brasileiro de Controle
do Cancer.
Tumor Specimens
Tumor slides were reviewed independently by two
pathologists and were classified according to the criteria
of the World Health Organization (WHO) Classification
of Tumors [14]. The Vancouver system was applied to
classify the tumors in low and high grades. A tumor was
considered high grade if it showed at least two of these
criteria: 1) predominantly papillary or solid growth pat-
tern, 2) 6 or more mitotic figures/10 high power fields,
or 3) severe nuclear atipia [15]. Peritumoral lymphovas-
cular space invasion (LVSI) was also evaluated for all
cases in the whole histological sections. A representative
peripheral area of the tumor was selected for the con-
struction of tissue microarray blocks and immunohisto-
chemical study.
Construction of tissue microarray (TMA) blocks
The tumor areas selected in the slides were marked in
the corresponding paraffin donor blocks and one cylin-
der of material (2.0 mm in diameter) was punched from
each case and mounted into recipient paraffin blocks at
1 mm intervals using a precision microarray instrument
(Beecher Instruments, Silver Spring, MD). A grid system
was established such that each core had an x and y
coordinate reference for sample identification. Blocks
were sealed at 60°C for 10 m. Three μm sections from
each TMA block were then prepared using standard
techniques and mounted on Starfrost® slides. The first
histological sections were stained by hematoxilin-eosin
and examined to be sure the correct areas were
included.
Immunohistochemistry analysis
Histological sections (3 μm) from TMA blocks were
quenched with 3% hydrogen peroxide solution in phos-
phate-buffered saline (PBS; Sigma, St. Louis, MO) for 20
m to block endogenous peroxidase activity. After several
washes in PBS, sections were heated in a microwave
(Electrolux, 900 W) for 15 m in 0.01 M citrate buffer,
pH 6.0 for antigen retrieval, then cooled at RT for 20 m.
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Sections were then incubated overnight with a 1:400
dilution of monoclonal antibody against human podo-
planin (clone D2-40, Dako, Carpinteria, CA). Podoplanin
is a glycoprotein specifically expressed by lymphatic
endothelial cells. In those tumor sections with negative
podoplanin staining, adjacent normal-appearing lympha-
tic endothelial cells served as positive internal controls.
Quantification of lymphatic microvessel density
Stained TMA histologic sections were analyzed using
standard light microscopy (Nikon, Eclipse 200). Under
low magnification, the most vascularized intratumoral
areas were identified. We counted the number of immu-
nostained lymphatic vessels found in 10 hot spot areas
at 400× magnification. Only vessels exhibiting typical
morphology (lumen) were considered lymphatic micro-
vessels (Figure 1). The LMVD for each case was
expressed by the mean value (total number of vessels in
10 hot spot microscopic fields/10). The median value of
all the mean LMVD was the cutoff to divide tumors in
high or low LMVD, as suggested by Hall et al.[16].
Statistical analyses
The association between categorical variables and lymph
node status and survival were evaluated using Pearson’s
Chi-square test. Kaplan & Meier method was used to
produce time life tables and survival curves.
A p-value less than 0.05 was considered significant.
The software used was Epi Infotm, Version 3.5.1. [17].
Results
The tumors were classified as endometrioid (44 cases,
77.2%) and non-endometrioid classified as serous (6
cases, 10.5%), clear cell (4 cases, 7%), undifferentiated (2
cases, 3.5%), and mixed (1 case, 1.7%). The association
between all the variables with lymph node status and
patient death are summarized in Table 1. The mean
number of lymphatic vessels counted in each patient’s
tumor sample ranged from 0 to 4.7. The median value
was 0.5 vessels and defined the value above and below
which was considered high and low LMVD, respectively.
Low LMVD was found in 27 (47.4%) patients, and high
LMVD was found in 30 (52.6%) patients. We observed
that low intratumoral LMVD was associated with poor
outcome. Seventy-five percent of deaths occurred in
patients with low intratumoral LMVD (p = 0.031). The
mean survival time observed in the group with low
LMDV was 79 months (confidence interval [62 - 96
months]) and the mean survival time for high LMDV
group was 129 months (confidence interval [113 - 145
months]). The difference was significant at 5% level. The
survival curves for both LMDV groups are presented at
Figure 2.
Low LMVD was also associated with miometrial and
adnaexal infiltration, cervical and peritoneal involve-
ment. Patients below 70 years presented higher LMVD
(21/33, 63.3%) than older patients (9/24, 37.5%)
although the difference did not reach statistical signifi-
cance. No association was seen between LMVD and
FIGO staging, histological type, vascular invasion, or
lymph node involvement (Table 2).
Positive lymph nodes were significantly associated with
histological grade (p = 0.001), vascular invasion (p =
0.017), FIGO stage (p < 0.001), myometrial infiltration
(p < 0,001), cervical infiltration (p = 0,023), adnaexal
involvement (p = 0,023) and peritoneal involvement (p =
0,048). Besides LMVD, death was associated with histolo-
gical type (p = 0.010), vascular invasion (p = 0.040), and
lymph node involvement (p = 0.025). Mean survival time
was 110 months (range of 84 - 135 months) for patients
with negative lymph node involvement, and 69 months
(range of 48 - 89 months) for patients with positive
lymph nodes.
Discussion
Lymphatic metastasis is one of the most important
prognostic factors for survival of patients with endome-
trial cancer as well as for other epithelial malignancies.
Many clinical and experimental data suggest that migra-
tion of tumor cells into the lymph nodes is facilitated by
lymphangiogenesis[18,19]. Studies evaluating lymphatic
neoformation and its role in tumoral migration are
facilitated by the recent identification of lymphangio-
genic factors and their receptors, and by lymphatic vas-
cular markers [5].
The most commonly used markers for immunohisto-
chemistry identification of lymphatic endothelial tissue
Figure 1 Immunohistochemistry staining of a histological
section of endometrioid carcinoma using D2-40 antibody
against podoplanin showing six lymphatic vessels. After
counting 10 high power fields, the mean was calculated for each
case. (Original magnification X400).
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include the vascular endothelial growth factor receptor 3
(VEGFR-3), PROX-1, LYVE-1, and podoplanin [5].
Among these, podoplanin, a 38 kDa mucin-type trans-
membrane glycoprotein which is recognized by the
monoclonal antibody D2-40, is considered the most reli-
able marker with a high specificity and sensitivity [5]. In
this study, we chose to evaluate podoplanin because it
was found to be expressed in lymphatic, but not blood
vascular endothelium [20], and is expressed in smaller
lymphatic vessels rather than larger ones [20], allowing
a more sensitive identification of lymphangiogenesis.
We then considered which compartment (intra or
peritumoral) to evaluate for lymphangiogenesis in this
study, as this is a source of great controversy in the lit-
erature. Since our knowledge of lymphangiogenesis in
different types of cancer is still limited, we decided that
it would be worthwhile to begin accumulating data. We
believe that a better understanding of the role of lym-
phangiogenesis in tumoral dissemination will only be
achieved after contributions from different researchers
groups.
In this study, we evaluated LMVD in the intratumoral
compartment using podoplanin as the lymphatic marker.
Vascular density was determined by direct counting of
vessels in 10 high power microscope fields. Although
our study is limited by the fact that LMVD was assessed
only in TMA sections, the area of the tumor that was
investigated was rigorously chosen considering fixation
conditions of the specimen, morphology of the tumor,
and the peripheral localization of the sample. Besides,
our cores had 2.0 mm in diameter, bigger than the con-
ventional cores.
LMVD has been studied in several cancers by various
methods [21]. There are few studies about LMVD in
gynecological cancer. Gombos et al. [9] studied intra-
and peritumoral LMVD using D2-40 immunohisto-
chemistry in 111 cervical squamous cell carcinomas and
correlated them with vascular endothelial growth factor
Table 1 Clinicopathological variables and association with lymph node status and outcome









Age 45-69 years 20 13 0.885 27 6 0.533
≥70 years 15 9 18 6
Histological type Endometrioid 30 14 0.053 38 6 0.010
Non-Endometrioid 5 8 7 6
Histological grade (Vancouver system) low 32 12 0.001 37 7 0.080
high 3 10 8 5
FIGO stage I 27 1 <0.001 24 4 0.303
II 4 0 4 0
III 3 19 15 7
IV 1 2 2 1
Vascular invasion no 12 3 0.017 14 1 0.040
yes 6 10 10 6
LMVD2 Low 14 13 0.160 18 9 0.031
high 21 9 27 3
Myometrial infiltration <50% 25 5 <0.001 26 4 0.113
>50% 9 17 18 8
Cervical infiltration no 25 9 0.023 31 3 0.003
yes 9 12 12 9
Adnaexal involvement no 33 14 0.023 31 6 0.004
yes 2 8 4 6
Peritoneal involvement no 28 13 0.048 33 8 0.811
yes 1 5 4 2
Total 57 34 22 45 12
1p value (Chi-square of Pearson); 2Intratumoral lymphatic microvessel density.
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(VEGF)-C expression, clinicopathologic tumor features,
and outcome. They found only high peritumoral LMVD
to be associated with poor overall survival. Zhang et al.,
using LYVE-1 (lymphatic vessel endothelial hyaluronan
receptor-1) as the lymphatic marker, studied intra- and
peritumoral lymphatic vascular density in early-stage
invasive cervical carcinomas. Both intravascular and
peritumoral high LMVD were associated with lymph
node metastasis [8]. In a conflicting study, Birner et al.
studied 95 cases of stage pTIb cervical carcinomas and
observed a more favorable prognosis among tumors
with high LMVD [10], a result that is similar to ours.
LMVD studies in endometrial cancer are extremely
limited. To investigate whether increased peritumoral
and intratumoral LMVD was a good prognostic factor
for nodal metastasis, Gao et al. studied 102 patients
with endometrial carcinoma using LYVE-1 as the lym-
phatic marker [22]. They found peritumoral but not
intratumoral high LMVD to be associated with lymph
node metastases. Vandenput et al. studied 62 patients
with endometrial carcinoma and found that neither peri-
tumoral nor intratumoral lymphangiogenesis determined
by podoplanin expression were related to prognosis [11].
Donughue et al. evaluated lymphatic vessel density
(LVD) in 17 cases of endometrial carcinomas by count-
ing vessels expressing D2-40. Intratumoral LVD was sig-
nificantly increased when compared with endometrial
functionalis LVD, but not when compared with endo-
metrial basalis LVD. They also observed a tendency
towards increased intratumoral LVD in grade 3 tumors
compared with grade 1 tumours [23]. Other studies
have documented lymphatic metastases independent of
intratumoral lymphatic vessels suggesting that the intra-
tumoral lymphatic vasculature is usually not functioning
and only peritumoral lymphatic vessels conduct fluid
and cells [24].
In our study, low LMVD was associated with poor
outcome. Seventy-five percent of deaths occurred in
patients with low intratumoral LMVD compared with
only 25% of deaths in patients with high LMVD (p =
0.031). In contrast, high LMVD was associated with
favorable prognostic factors. High LMVD tumors were
associated with less myometrial infiltration > 50% (31%
vs. 63%, p = 0.034), less cervical involvement (24.1% vs.
53.8%, p = 0.023), and less peritoneal involvement (4%
vs. 29.4%, p = 0.055). The explanation for this finding is
not clear, but we can suppose that lymphangiogenesis is
an early event in tumor progression, when lymphatic
vessels are still not functional. Considering that higher
LMVD was present in early anatomic tumors with no
association with intrinsic tumors biological characteris-
tics, as histological type or grade, we can suppose that
this is an event related to the first steps of local interac-
tion between tumor and microenvironment. Besides,
high LMVD was associated with favorable outcome,
indicating that it might be clinically relevant. However,
it must be pointed that the vascular density results from
a more complex biologic process that involves a cross-
talk between tumor, vessels and host stroma. Our
results showed higher LMVD among tumor in the initial
Figure 2 Overall survival curve stratified for high and low intratumoral lymphatic microvessel density (LMVD).
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steps of invasion (no extrauterine extension) and better
prognosis. It is well known the role of normal lymphatic
vasculature in maintaining tissue homeostasis [25]. The
lymphatic network must be investigated not only by its
anatomic density, as we did, but also functionally. We
need intensive further investigation with more early
cases and adequate follow up, to explore the role of vas-
cular density in the tumoral progression. These future
results may help elucidate pathways of lymphangiogen-
esis leading to identification of potential drug targets for
endometrial carcinomas. Considering our preliminary
results, it is possible that the target would not be the
lymphatic vessel itself, but some other molecules
involved with its function.
Conclusions
Our results show that high intratumoral LMVD is a
characteristic of endometrial carcinomas with lesser
extrauterine extension and is associated with better out-
come. However, further studies with larger series are
needed to elucidate the biological meaning of these
intriguing findings.
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